ArticleInternational journal of pharmaceutics: X2026
A ROS-responsive nanozyme delivering gallic acid synergistically ameliorates chronic rhinosinusitis via epithelial barrier restoration and Syk/NF-κB inhibition.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanozyme-Mediated Joint Homeostasis Restoration: Emerging Strategies for Arthritis Therapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic rhinosinusitis (CRS) is a prevalent inflammatory disorder characterized by persistent mucosal inflammation and epithelial barrier dysfunction. However, effective therapeutic strategies targeting this core pathophysiology remain limited. Gallic acid (GA)-a polyphenol with known anti-inflammatory activity-suffers from poor bioavailability and the absence of targeted delivery, limiting its clinical translation. Methods: We engineered a reactive oxygen species (ROS)-responsive nanozyme, termed Ce-MOF-Pt@GA@PDA-TK-PEG (CP-GA-PKP), designed for targeted therapy of CRS. The material was characterized to confirm its structure and ROS-responsive properties. Its therapeutic efficacy was evaluated in a murine CRS model, with assessments focusing on inflammatory cell infiltration as well as the levels of ZO-1 and Occludin. Network pharmacology was employed to identify the molecular target of GA, which was subsequently validated through in vitro experiments using human nasal epithelial cells by analyzing the Syk/NF-κB pathway and downstream inflammatory cytokines. Results: In CRS mice, nanozyme treatment significantly alleviated nasal mucosal inflammation, reduced inflammatory cytokine levels, and restored Occludin and ZO-1 expression, indicating epithelial barrier repair. Network pharmacology identified Syk as the primary target of GA. Consistently, in vitro studies confirmed that the nanozyme inhibited the phosphorylation of Syk and its downstream effector NF-κB, thereby reducing pro-inflammatory cytokine levels. Conclusion: Our findings demonstrate that this ROS-responsive nanozyme provides a novel and effective therapeutic strategy for CRS in preclinical models, warranting further pharmacokinetic and toxicological evaluation to support clinical translation. It exerts synergistic therapeutic effects through a dual mechanism: by inhibiting the Syk/NF-κB signaling axis to suppress inflammation, and by protecting epithelial barrier integrity. A promising nanotherapeutic strategy is proposed and the molecular mechanism underlying GA's action in CRS is investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.